1255 related articles for article (PubMed ID: 15483602)
1. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S
Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602
[TBL] [Abstract][Full Text] [Related]
2. Neurodegenerative disease: neuron protection agency.
Orr HT
Nature; 2004 Oct; 431(7010):747-8. PubMed ID: 15483586
[No Abstract] [Full Text] [Related]
3. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.
Miller J; Arrasate M; Shaby BA; Mitra S; Masliah E; Finkbeiner S
J Neurosci; 2010 Aug; 30(31):10541-50. PubMed ID: 20685997
[TBL] [Abstract][Full Text] [Related]
4. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
Lunkes A; Mandel JL
Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
[TBL] [Abstract][Full Text] [Related]
5. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.
Muchowski PJ; Ning K; D'Souza-Schorey C; Fields S
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):727-32. PubMed ID: 11792857
[TBL] [Abstract][Full Text] [Related]
6. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.
Humbert S; Bryson EA; Cordelières FP; Connors NC; Datta SR; Finkbeiner S; Greenberg ME; Saudou F
Dev Cell; 2002 Jun; 2(6):831-7. PubMed ID: 12062094
[TBL] [Abstract][Full Text] [Related]
7. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
9. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
[TBL] [Abstract][Full Text] [Related]
10. Selection of behaviors and segmental coordination during larval locomotion is disrupted by nuclear polyglutamine inclusions in a new Drosophila Huntington's disease-like model.
Nishimura Y; Yalgin C; Akimoto S; Doumanis J; Sasajima R; Nukina N; Miyakawa H; Moore AW; Morimoto T
J Neurogenet; 2010 Dec; 24(4):194-206. PubMed ID: 21087194
[TBL] [Abstract][Full Text] [Related]
11. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
[TBL] [Abstract][Full Text] [Related]
12. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
[TBL] [Abstract][Full Text] [Related]
13. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
Nguyen T; Hamby A; Massa SM
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
[TBL] [Abstract][Full Text] [Related]
14. Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.
Mitra S; Tsvetkov AS; Finkbeiner S
J Biol Chem; 2009 Feb; 284(7):4398-403. PubMed ID: 19074152
[TBL] [Abstract][Full Text] [Related]
15. Distinct aggregation and cell death patterns among different types of primary neurons induced by mutant huntingtin protein.
Tagawa K; Hoshino M; Okuda T; Ueda H; Hayashi H; Engemann S; Okado H; Ichikawa M; Wanker EE; Okazawa H
J Neurochem; 2004 May; 89(4):974-87. PubMed ID: 15140196
[TBL] [Abstract][Full Text] [Related]
16. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
[TBL] [Abstract][Full Text] [Related]
17. Are there multiple pathways in the pathogenesis of Huntington's disease?
Aronin N; Kim M; Laforet G; DiFiglia M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):995-1003. PubMed ID: 10434298
[TBL] [Abstract][Full Text] [Related]
18. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
[TBL] [Abstract][Full Text] [Related]
19. Protein aggregation in Huntington's disease.
Hoffner G; Djian P
Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
[TBL] [Abstract][Full Text] [Related]
20. Huntingtin processing in pathogenesis of Huntington disease.
Qin ZH; Gu ZL
Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
